Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals plc reported that its SVP, Chief Accounting Officer Patricia Carr exercised 1,250 non-qualified stock options at an exercise price of $140.03 per share on November 4, 2026, acquiring 1,250 ordinary shares. That day, Carr sold 1,250 ordinary shares at $231.37 per share and 163 ordinary shares at $231.27 per share. The option transaction reports 3,000 options following the exercise. No Rule 10b5-1 plan is reported.
Jazz Pharmaceuticals plc (JAZZ) director Bruce Cozadd filed a notice for a proposed sale of 68,808 common shares, with an aggregate market value of $16,235,515.95 and an approximate sale date of November 6, 2026. The shares are identified as acquired through a stock option exercise from the issuer, with cash payment; Morgan Stanley Smith Barney LLC is listed as broker. The notice also lists earlier sales of 6,000 shares on November 2, October 1 and September 1, and 1,219 shares on August 31, 2026.
Jazz Pharmaceuticals plc President & CEO Renee D. Gala sold 1,000 ordinary shares on November 3, 2026, at $225.37 per share, leaving her with 140,394 shares held directly. The transaction was made automatically under a Rule 10b5-1 plan adopted on June 4, 2026; the footnote states it was not discretionary.
Jazz Pharmaceuticals plc (JAZZ) is the subject of an amended beneficial-ownership report in which FMR LLC and Abigail P. Johnson each listed beneficial ownership of 5,601,907 shares, or 8.6% of the common-stock class. FMR LLC reported sole voting power over 5,544,405 shares and sole dispositive power over 5,601,907 shares. Abigail P. Johnson reported no voting power and sole dispositive power over 5,601,907 shares.
Jazz Pharmaceuticals plc director Bruce C. Cozadd sold 6,000 ordinary shares on November 2, 2026, at $215.84 per share. He reported direct ownership of 339,875 ordinary shares after the sale. The transaction occurred automatically under a Rule 10b5-1 plan adopted on November 26, 2025, and the footnote states it was not discretionary.
Jazz Pharmaceuticals plc (JAZZ) reported a proposed sale of 1,413 common shares for the account of officer Patricia Carr, who signed as Patricia Josephine Carr. The shares have an aggregate market value of $326,909.51. The approximate sale date is November 4, 2026, and NASDAQ is listed as the exchange.
Jazz Pharmaceuticals plc (JAZZ) is named in a Rule 144 notice concerning officer and director Renee D. Gala’s proposed sale of 1,000 common shares, with an aggregate market value of $225,370, on November 3, 2026, through Morgan Stanley Smith Barney LLC on Nasdaq. The notice identifies the shares as restricted stock acquired from the issuer on June 30, 2026. It also reports sales of 2,000 shares on October 6, 2026, for $472,800 and 2,000 shares on September 8, 2026, for $486,060.
Jazz Pharmaceuticals plc (JAZZ) officer Bruce C. Cozadd reported a proposed sale of 6,000 common shares, with an aggregate market value of $1,295,040. Merrill Lynch is listed as the broker, NASDAQ as the exchange, and November 2, 2026 as the approximate sale date.
Jazz Pharmaceuticals plc (JAZZ) reported third-quarter 2026 revenue of $1,243.0 million, compared with $1,126.1 million a year earlier. It recorded a net loss of $483.4 million, versus net income of $251.4 million, including $754.2 million of acquired in-process research and development expense, compared with $42.5 million a year earlier. For the nine months ended September 30, 2026, revenue was $3,520.2 million and operating cash flow was $1,330.0 million, compared with $3,069.6 million and $993.3 million, respectively.
In September 2026, Jazz completed its acquisition of Actio for an upfront payment of $820.0 million, net of cash acquired, with up to $500.0 million in additional regulatory and commercial milestone payments. The acquisition added ABS-1230 to Jazz’s clinical pipeline and made Actio a wholly owned subsidiary. In August 2026, its wholly owned finance subsidiary, Jazz Investments, completed a private offering of $1.3 billion aggregate principal amount of 2032 Notes. After a share-price condition was met in the quarter ended September 30, 2026, holders may exchange the 2030 Notes during the quarter ending December 31, 2026.
Jazz Pharmaceuticals plc reported third-quarter 2026 revenue of $1.243 billion, up 10% year over year, and a GAAP net loss of $483.4 million; non-GAAP adjusted net loss was $250.8 million. Both loss measures included $754.2 million of acquired in-process research and development expense allocated to ABS-1230 (JZP6979) in the Actio acquisition.
The company raised full-year 2026 revenue guidance to $4.775–$4.850 billion, from $4.600–$4.750 billion. It generated $1.330 billion of cash from operations in the first nine months of 2026. Ziihera was approved and launched for first-line HER2-positive GEA, and the Actio acquisition closed in September, adding ABS-1230 to its rare epilepsy portfolio.
In the third quarter, Jazz completed a private placement of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 and repurchased $225 million of ordinary shares using existing cash. In October, the board approved repurchases of up to $500 million with no expiration date. The company also amended and extended Term Loan B, lowering its applicable margin by 50 basis points and extending maturity by five years to May 2033.